EFFECTIVE this month, Janssen's Prezcobix (darunavir/cobicistat) is available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral agents.
The product is a fixed dose, once daily antiretroviral combination film-coated tablet and is indicated for treatment-nave and treatment-experienced adults with no darunavir resistance associated mutations.
Each daily tablet of Prezcobix contains 800 mg of the HIV-1 protease inhibitor (PI) darunavir (as in Prezista) and 150 mg of cobicistat (as in Tybost), a pharmacokinetic enhancer, or 'boosting' agent developed by Gilead Sciences.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Oct 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Oct 16